Search results
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 3 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
The Motley Fool via AOL· 5 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 9 hours agoAstraZeneca’s targeted therapy could see wider use after ASCO data. Elsewhere, Caribou sought to...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 1 day agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 10 hours agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 11 hours agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 5 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Motley Fool via Yahoo Finance· 5 days agoAstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
The Motley Fool via AOL· 5 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...